42.66

1.46% -0.63

After Hours: 42.66

Supernus Pharmaceuticals Inc (SUPN)

Overview News Price History Option Chain Financials Why SUPN Down? Discussions Forecast

Supernus Pharmaceuticals Inc stock is traded at $42.66, with a volume of 607.46K. It is down -1.46% in the last 24 hours and down -5.95% over the past month. Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Previous Close:

$43.29

Open:

$43.21

24h Volume:

607.46K

Relative Volume:

0.73

Market Cap:

$2.48B

Revenue:

$776.83M

Net Income/Loss:

$-29.02M

P/E Ratio:

-83.32

EPS:

-0.512

Net Cash Flow:

$82.25M

1W Performance:

+1.57%

1M Performance:

-5.95%

6M Performance:

-14.78%

1Y Performance:

-9.58%

1-Day Range:

$42.65

$43.69

1-Week Range:

$41.68

$44.46

52-Week Range:

$40.51

$59.68

Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile

Name

Supernus Pharmaceuticals Inc

Sector

Healthcare (1067)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

301-838-2500

Address

9715 KEY WEST AVENUE, ROCKVILLE, MD

Employee

778

Twitter

@Supernus_Pharma

Next Earnings Date

2026-11-03

Latest SEC Filings

SUPN's Discussions on Twitter

Compare SUPN vs TAK, TEVA, HLN, ZTS, VTRS

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SUPN Supernus Pharmaceuticals Inc	42.66	2.48B	776.83M	-29.02M	82.25M	-0.512
TAK Takeda Pharmaceutical Co Adr	18.86	60.23B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	39.19	45.71B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.26	40.72B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	71.05	29.36B	9.51B	2.64B	2.14B	6.0361
VTRS Viatris Inc	17.83	20.48B	14.57B	-296.50M	1.64B	-0.259

Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-09-25	Upgrade	Piper Sandler	Neutral → Overweight
Jul-30-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Feb-19-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-06-25	Initiated	Cantor Fitzgerald	Overweight
Sep-11-24	Downgrade	Piper Sandler	Overweight → Neutral
Jan-03-23	Resumed	Jefferies	Buy
Dec-01-21	Resumed	Jefferies	Buy
Apr-13-21	Upgrade	Jefferies	Hold → Buy
Jun-16-20	Upgrade	Piper Sandler	Neutral → Overweight
Jun-15-20	Resumed	Jefferies	Hold
Nov-08-19	Downgrade	Berenberg	Buy → Hold
Nov-07-19	Downgrade	Stifel	Buy → Hold
Nov-06-19	Downgrade	Jefferies	Buy → Hold
Nov-12-18	Reiterated	B. Riley FBR	Buy
Jan-18-18	Reiterated	B. Riley FBR, Inc.	Buy
Dec-28-17	Reiterated	B. Riley FBR, Inc.	Buy
Dec-04-17	Upgrade	Janney	Neutral → Buy
Nov-08-17	Upgrade	Stifel	Hold → Buy
Oct-19-17	Initiated	FBR & Co.	Buy
Sep-19-17	Downgrade	Stifel	Buy → Hold
Jul-17-17	Downgrade	Piper Jaffray	Overweight → Neutral
Jul-14-17	Initiated	Janney	Neutral
Jun-01-17	Upgrade	Piper Jaffray	Neutral → Overweight
Jul-18-16	Downgrade	Northland Capital	Outperform → Market Perform
Jul-18-16	Downgrade	Piper Jaffray	Overweight → Neutral
Feb-08-16	Upgrade	Jefferies	Hold → Buy
Nov-05-15	Reiterated	Northland Capital	Outperform
Oct-28-15	Initiated	Northland Capital	Outperform

View All

Supernus Pharmaceuticals Inc Stock (SUPN) Latest News

05:09 AM